What is ATOS's current stock price?

ATOS (Atossa Therapeutics, Inc.) is currently trading at $4.96 with a market cap of $42.7M.

What sector is Atossa Therapeutics, Inc. in?

Atossa Therapeutics, Inc. (ATOS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ATOS a good stock to buy?

Analysts have a Buy consensus on ATOS with a price target of $10.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ATOS Atossa Therapeutics, Inc.

Healthcare

$4.96-0.20%ClosedMarket Cap: $42.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.40

P/S

0.00

EV/EBITDA

-0.28

DCF Value

$4.34

FCF Yield

-78.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-84.9%

ROA

-99.2%

ROIC

-129.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-9.6M	$—
Q4 null	$0.00	$-10.9M	$—
FY null	$0.00	$-34.8M	$—
Q3 null	$0.00	$-8.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$10.00

Target (Median)

$10.00

Target Range

$10.00 - $10.00

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Ascendiant CapitalBuy

2026-04-10

HC Wainwright & Co.Buy

2026-03-26

Ascendiant CapitalBuy

2025-12-08

Ascendiant CapitalBuy

2025-09-22

Ascendiant CapitalBuy

2025-06-06

Trading Activity

Insider Trades

View All

Steinhart Richard Idirector

SellThu May 14

Remmel H. Lawrencedirector

SellThu May 14

Galli Stephen Jdirector

SellThu May 14

Finn Jonathandirector

SellThu May 14

Cigler Tessadirector

SellThu May 14

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.25

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Peers

TIL